Cagrilintide 5mg + Semaglutide 10mg Research Compound – Premium Amylin/GLP-1 Dual-Mech Blend

Welcome to Liaocheng Yixin Company, your trusted source for premium research peptides including the cagrilintide semaglutide 5mg/10mg blend for research. As a licensed peptide synthesis manufacturer operating from our facility in Shandong Province, China, we provide high-quality research compounds for the global scientific community. cagrilintide semaglutide 5mg 10mg blend for research

This research blend combines cagrilintide (5mg), a long-acting amylin analog, with semaglutide (10mg), a well-characterized GLP-1 receptor agonist. The pairing targets two distinct receptor families—calcitonin/amylin receptors and incretin receptors—that converge on appetite regulation and metabolic pathways. When you buy cagrilintide semaglutide blend for research, you gain access to a dual-mechanism tool for investigating metabolic regulation, energy homeostasis, and receptor pharmacology.

What is the Cagrilintide & Semaglutide Research Blend?

This 15mg research blend (5mg + 10mg) combines two peptides with complementary mechanisms for metabolic research:

Cagrilintide (CAS 1415456-99-3, sequence: {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2, disulfide bridge: Cys3-Cys8) is a long-acting analogue of the pancreatic β-cell hormone amylin .

Mechanism of Action in Research

The blend combines two distinct but complementary receptor pathways:

Cagrilintide (Amylin Pathway)

Cagrilintide engages the amylin receptor—a heteromeric complex formed by the calcitonin receptor plus a receptor activity-modifying protein (RAMP). Amylin is co-secreted with insulin from pancreatic beta cells and exerts satiating effects via both homeostatic and hedonic brain regions . Research effects include:

• Brainstem satiety signaling via area postrema receptors—a brain region distinct from hypothalamic GLP-1 targets 

• Gastric emptying modulation, slowing food transit from the stomach 

• Glucagon suppression—reducing the counter-regulatory hormone that opposes insulin 

• cagrilintide semaglutide 5mg 10mg blend for research

Semaglutide (GLP-1 Pathway)

Semaglutide engages the GLP-1 receptor, part of the incretin receptor family. It reduces appetite via hypothalamic GLP-1 receptors, increases insulin production, and decreases glucagon secretion, delaying gastric emptying .

Dual-Pathway Synergy

Cagrilintide engages the calcitonin receptor family, while semaglutide engages the incretin receptor family—two completely separate receptor systems . When combined, these non-overlapping pathways converge on the same downstream metabolic outcomes (appetite regulation, glucose homeostasis), creating a mechanistic rationale for enhanced research effects .

Research Applications

Metabolic and Obesity Research

CagriSema has been the subject of extensive clinical investigation. A phase 2 dose-finding trial reported that cagrilintide 2.4 mg, as an adjunct to diet and exercise, resulted in a bodyweight reduction of 10% versus 3% with placebo after 26 weeks . The phase 3 REDEFINE programme has evaluated the 2.4 mg/2.4 mg fixed-dose combination in adults with obesity .

GLP-1/Amylin Pathway Synergy Studies

Researchers use this blend to investigate how two different receptor systems—amylin/calcitonin and GLP-1—converge on appetite regulation and energy balance. The non-overlapping receptor engagement provides a model for studying additive/synergistic metabolic effects . cagrilintide semaglutide 5mg 10mg blend for research

Comparative Mechanism Research

The blend can be compared to single-mechanism interventions (cagrilintide or semaglutide alone) to study the contribution of each pathway to metabolic outcomes .

Key Research Findings

A systematic review and meta-analysis of four randomized controlled trials (4,751 patients) found that CagriSema was associated with a substantial reduction in percent change in body weight when compared with placebo, cagrilintide monotherapy, and semaglutide monotherapy . Additional meta-analysis demonstrated CagriSema resulted in additional absolute weight reduction of 9.11 kg compared to semaglutide alone .

The REDEFINE 4 trial reported that CagriSema achieved 23% weight loss after 84 weeks of treatment in people with obesity . The open-label trial included 809 randomized participants with mean baseline body weight of 114.2 kg . cagrilintide semaglutide 5mg 10mg blend for research

Why Choose Liaocheng Yixin Company?

When sourcing cagrilintide semaglutide 5mg/10mg blend for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards and follows rigorous protocols for peptide synthesis.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC and mass spectrometry. Our blend meets ≥99% purity standards. Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Components: Cagrilintide (5mg) + Semaglutide (10mg)

• CAS Number: 1415456-99-3

• Form: Lyophilized powder

• cagrilintide semaglutide 5mg 10mg blend for research

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture

• Form: Lyophilized powder for research use

Quality Assurance & Testing

Every batch undergoes comprehensive quality control: